Tatiana N. Zabotina

Tatiana N. Zabotina

Auto-generated profile, based on publicly available information

Tatiana N. Zabotina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2016 in Russian Journal of Oncology
Verified
Journal Article
Open access
PDF file
TZTat’yana N. Zabotina
Tat’yana N. Zabotina
OKO. V Korotkova
O. V Korotkova
ABA. A Borunova
A. A Borunova
DTD. V Tabakov
D. V Tabakov
IBI. I Bokin
I. I Bokin
КГКадагидзе З. Г
Кадагидзе З. Г
For the first time in Russia the immunophenotype of tumor infiltrated lymphocytes (TIL) was investigated with the use of a method of quantitative flow cytometry. Samples from 104 patients, suffering from solid tumors (such as breast cancer, ovarian cancer, melanoma and oral cavity squamous carcinoma), were analyzed in this investigation. In the difference of cytomorphological analysis, the method of flow cytometry identified TIL in 100% of cases. In the structure of CDS+Т- lymphocytes the ratio CD4/CD8 was equal to 1,1±0,1. Serial gating strategy allowed to assess minor subpopulations of regulatory T-lymphocytes CD45+CD4+CD127+low/neg and CD45+CD8+CD28-CD11b-. Regulatory mechanisms with involvement of CD8 T-cells played the main role in the generation of immune responses at the tissue level ofpatients, suffering from solid tumors, independent of nosological form of disease.

5 August 2024 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
OVOlga Aleksandrovna Vlasova
Olga Aleksandrovna Vlasova
IAIrina Antonova
Irina Antonova
RZRoman Germanovich Zenkov
Roman Germanovich Zenkov
DNDenis Sergeevich Naberezhnov
Denis Sergeevich Naberezhnov
GBGennady A. Belitsky
Gennady A. Belitsky
MYMarianna G Yakubovskaya
Marianna G Yakubovskaya
Background: Many plant secondary metabolites (PSMs) were shown to intercalate into DNA helix or interact with DNA grooves. This may influence histone-DNA interactions changeing chromatin structure and genome functioning. Methods: Nucleosome stability and linker histone H1.2, H1.4 and H1.5 localizations were studied in HeLa cells after the treatment with 15 PSMs, which are DNA-binders and possess anticancer activity according to published data. Chromatin remodeler CBL0137 was used as a control. Effects of PSMs were studied using fluorescent microscopy, flowcytometry, quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR), western-blotting. Results: We showed that 1-hour treatment with CBL0137 strongly inhibited DNA synthesis and caused intensive linker histone depletion consistent with nucleosome destabilization. None of PSMs caused nucleosome destabilization, while most of them demonstrated significant influence on linker histone localizations. In particular, cell treatment with 11 PSMs at non-toxic concentrations induced significant translocation of the histone H1.5 to nucleoli and most of PSMs caused depletion of the histones H1.2 and H1.4 from chromatin fraction. Curcumin, resveratrol, berberine, naringenin, and quercetin caused significant redistribution of all three variants of the studied linker histones showing some overlap of PSM effects on linker histone DNA-binding. We demonstrated that PSMs, which induced the most significant redistribution of the histone H1.5 (berberine, curcumin and naringenin), influence the proportion of cells synthesizing DNA, expressing or non-expressing cyclin B and influence cell cycle distribution. Berberine induction of H1.5 translocations to nucleoli was shown to occur independently on the phases of cell cycle (metaphase was not analyzed). Conclusions: For the first time we revealed PSM influence on linker histone location in cell nuclei that opens a new direction of PSM research as anticancer agents.

28 November 2018 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
TZT. N. Zabotina
T. N. Zabotina
OKO. V. Korotkova
O. V. Korotkova
ACA. I. Chertkova
A. I. Chertkova
EZE. N. Zakharova
E. N. Zakharova
DTDmitrii V. Tabakov
Dmitrii V. Tabakov
ZKZ. G. Kadagidze
Z. G. Kadagidze

7 October 2021 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
TZT. N. Zabotina
T. N. Zabotina
ACA. I. Chertkova
A. I. Chertkova
ABA. A. Borunova
A. A. Borunova
EZE. N. Zakharova
E. N. Zakharova
ESE. K. Shoua
E. K. Shoua
AKA. G. Kadagidze
A. G. Kadagidze
Introduction. Breast cancer (BC) is an immunogenic tumor. Immune cells infiltration of tumor tissue can affect the clinical course of the disease. The immunogenicity of breast cancer varies depending on the molecular subtype.The aim of this work was to study the main indicators of systemic and local immunity before patient’s treatment and to determine their relationship with the immediate neoadjuvant chemotherapy results.Materials and methods. Patients with stage II–III BC received standard neoadjuvant chemotherapy in accordance with the molecular subtypes. The percentage of the main effector and regulatory lymphocytes populations of systemic and local immunity was determined by flow cytometry.Results. A decrease in the level of effector CD8 and CD4 lymphocyte populations and an increase in the level suppressor populations in tumor tissue in comparison with peripheral blood indicate an immunosuppressive state of local immunity in BC patients. In tumor tissue, a high level of CD8+ PD-1+ and CD4+ PD-1+ cells were associated with a high level of regulatory CD4+ CD25highCD127–/low and CD8+ CD11b– CD28– lymphocytes. Differences were found in the significance of individual lymphocyte populations for the immediate results of treatment between patients with different subtypes of breast cancer.Conclusion. Determination of lymphocyte subpopulations correlating with the level of PD-1 cells, and the results of treatment in patients with different molecular BC subtypes, will help a clearer understanding of the antitumor immune response in this pathology, and will also serve as a basis for identifying immune biomarkers that can be used as additional predictive factors in various treatment options for BC patients.

1 January 2003
Verified
Journal Article
Closed access
TBT A Bogush
T A Bogush
AKA V Konukhova
A V Konukhova
ARA B Ravcheeva
A B Ravcheeva
TZT N Zabotina
T N Zabotina
ZKZ.G. Kadagidze
Z.G. Kadagidze
MDM I Davydov
M I Davydov

13 December 2018 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
GMG. Margolin
G. Margolin
AMA. М. Mudunov
A. М. Mudunov
IGI. M. Gelfand
I. M. Gelfand
YAYu. V. Alymov
Yu. V. Alymov
AAA. A. Akhundov
A. A. Akhundov
EZE. N. Zakharova
E. N. Zakharova
The study objective is to investigate the causes of insufficient efficiency of neck lymph node dissection and possibilities of its improvement in cancer of the oral mucosa without clinically detectable metastases.Materials and methods. A review of literature on surgical methods of affecting regional lymph collectors in cancers of the oral cavity was performed, and preliminary data on possibilities of biopsy of the sentinel lymph node were obtained.Conclusion. Combination of fluorescent lymph node mapping andflow cytometry allows to identify the sentinel lymph node and detect hidden micrometastases with high sensitivity.